Catalyst Calendar

Fri, Oct 2, 2026

1 updates

9:00 AM

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026 COPENHAGEN, Denmark,

Presentation / Abstract • Phase 2ESMO three-year data presentation Sat, Oct 24, 2026evaxion.ai

Mon, Sep 14, 2026

1 updates

EVAX

8:00 AM

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and

evaxion.ai

Thu, Aug 20, 2026

1 updates

EVAX

7:30 AM

Evaxion announces business update and second quarter 2026 financial results

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.

Presentation / Abstract • Phase 2evaxion.ai

Mon, Aug 17, 2026

1 updates

EVAX

8:00 AM

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs.

evaxion.ai

Fri, Aug 14, 2026

1 updates

EVAX

8:00 AM

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026,

evaxion.ai

Fri, Jul 17, 2026

1 updates

EVAX

7:15 AM

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented

Presentation / Abstract • Phase 2ESMO poster presentation Sat, Oct 24, 2026, 12:00 PM CETevaxion.ai